- ICH GCP
- US Clinical Trials Registry
- Search trials
Clinical Trials on Locally Advanced Unresectable HER2-Negative Breast Carcinoma in Korea, Republic of
Total 162 results
-
EnhancedBio USA Inc.ZenopharmRecruitingMetastatic Breast Cancer | Locally Advanced Breast Cancer | HER2-Negative | Estrogen Receptor-PositiveUnited States, Korea, Republic of
-
Txinno Bioscience Inc.RecruitingLocally Advanced (Unresectable) or Metastatic Solid TumorsKorea, Republic of
-
Samsung Medical CenterActive, not recruitingTriple Negative Breast Cancer | HER2-positive Breast CancerKorea, Republic of
-
Yonsei UniversityCompleted
-
Gangnam Severance HospitalSeoul National UniversityRecruitingBreast Cancer | HER2-negative Breast Cancer | Estrogen Receptor Positive Tumor | Premenopausal Breast Cancer | Node-positive Breast CancerKorea, Republic of
-
Hoffmann-La RocheActive, not recruitingEstrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast CancerUnited States, Korea, Republic of, China, Poland, Taiwan, Turkey, United Kingdom, Australia, Argentina, Germany, Singapore, Thailand, Israel, Russian Federation, Ukraine, Brazil, South Africa
-
Seoul National University HospitalTerminatedMetaplastic Breast CarcinomaKorea, Republic of
-
Gangnam Severance HospitalSamsung Medical Center; Asan Medical Center; Severance HospitalRecruitingBreast Cancer | Surgery | Recurrent Breast Cancer | Estrogen Receptor Positive Tumor | Stereotactic Body Radiotherapy | Her2-negative TumorKorea, Republic of
-
Yonsei UniversityCompletedHER2 Positive Advanced/Metastatic/Nonresectable Biliary Tract CancerKorea, Republic of
-
Yonsei UniversityNot yet recruitingHER2 Positive Advanced/Metastatic/Nonresectable Biliary Tract CancerKorea, Republic of
-
R-PharmCompletedMetastatic Breast Cancer | Triple Negative Locally Advanced Non-resectable Breast CancerCzech Republic, Italy, Poland, Spain, Austria, France, Greece
-
Yonsei UniversityCompletedHepatocellular Carcinoma, Unresectable, AdvancedKorea, Republic of
-
Genentech, Inc.RecruitingEstrogen Receptor (ER)-Positive, HER2-negative, Locally Advanced or Metastatic Breast CancerKorea, Republic of, United States, Spain, Taiwan, United Kingdom, Japan, Germany, Argentina, Turkey, Greece, Italy, Singapore, South Africa
-
Yonsei UniversityRecruitingTriple Negative Breast Cancer | Metastatic Breast Cancer With HER2 PositiveKorea, Republic of
-
Hoffmann-La RocheActive, not recruitingEstrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast CancerUnited States, Italy, Korea, Republic of, Canada, Germany, United Kingdom, Australia, Belgium, Brazil, China, Denmark, France, Hong Kong, Portugal, Spain, Taiwan, Turkey, Japan, Argentina, Mexico, Israel, Poland, Russian Federation, A... and more
-
Eisai Korea Inc.CompletedLocally Advanced or Metastatic Breast CancerKorea, Republic of
-
National Cancer Centre, SingaporeHoffmann-La Roche; Sirtex Medical; Singapore Clinical Research InstituteRecruitingLocally Advanced Hepatocellular CarcinomaKorea, Republic of, Singapore
-
CHA UniversityRecruitingLocally Advanced CholangiocarcinomaKorea, Republic of
-
Vaxcell Bio, Co., Ltd.CompletedLocally Advanced Hepatocellular CarcinomaKorea, Republic of
-
QuantumLeap Healthcare CollaborativeRecruitingBreast Cancer | Breast Neoplasms | Breast Tumors | HER2-positive Breast Cancer | Angiosarcoma | Locally Advanced Breast Cancer | HER2-negative Breast Cancer | TNBC - Triple-Negative Breast Cancer | Hormone Receptor Positive Tumor | Hormone Receptor Negative Tumor | Early-stage Breast CancerUnited States
-
AstraZenecaCompletedMetastatic Breast Cancer | Locally Advanced orKorea, Republic of
-
AstraZenecaCompletedER+ HER2- Advanced Breast CancerUnited States, United Kingdom, Korea, Republic of
-
Seoul National University HospitalClinical Research Center for Solid Tumor, KoreaCompletedLocally Advanced Head and Neck Squamous Cell CarcinomaKorea, Republic of
-
Seoul National University HospitalAstraZeneca; Korean Cancer Study GroupCompletedLocally Advanced or Metastatic NSCLCKorea, Republic of
-
National Cancer Institute (NCI)Active, not recruitingAnatomic Stage III Breast Cancer AJCC v8 | Anatomic Stage IV Breast Cancer AJCC v8 | Recurrent Breast Carcinoma | HER2/Neu Negative | Breast Adenocarcinoma | Metastatic Breast Carcinoma | Locally Advanced Breast CarcinomaUnited States, South Africa
-
Olema Pharmaceuticals, Inc.RecruitingBreast Cancer | Advanced Breast Cancer | Metastatic Breast Cancer | HER2 Negative Breast Carcinoma | ER Positive Breast CancerUnited States, Korea, Republic of, Australia, Taiwan, Hong Kong, Malaysia, Thailand, Argentina, Belgium, Portugal, Italy, Czechia, Mexico, Poland
-
National Cancer Institute (NCI)GlaxoSmithKlineCompletedStage IV Breast Cancer | Recurrent Breast Carcinoma | Invasive Breast Carcinoma | Estrogen Receptor Negative | HER2/Neu Negative | Progesterone Receptor Negative | Triple-Negative Breast CarcinomaUnited States
-
Samsung Medical CenterCompletedLocally Advanced or Metastatic Non-clear Cell Type Renal Cell CarcinomaKorea, Republic of
-
Gilead SciencesEverest MedicinesActive, not recruitingLocally Advanced or Metastatic Unresectable Urothelial CancerUnited States, Belgium, France, Spain, United Kingdom, Korea, Republic of, Czechia, Germany, Israel, China, Italy, Australia, Hong Kong, Taiwan, Portugal, Singapore, Croatia, Greece, Turkey, Sweden, Switzerland, Canada, Austria, Bulgaria and more
-
Yonsei UniversityNot yet recruitingLocally Advanced Nasopharyngeal CarcinomaKorea, Republic of
-
Novartis PharmaceuticalsCompletedSquamous Cell Carcinoma of Head and Neck | Esophageal Squamous Cell Carcinoma | HER2 + Breast Cancer, HER2 + Gastric Cancer, Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma | HER2 + Breast Cancer | HER2 + Gastric CancerTaiwan, Spain, Canada, Korea, Republic of, United States
-
AstraZenecaActive, not recruitingAdvanced ER-Positive HER2-Negative Breast CancerUnited States, Italy, Spain, Belgium, Poland, Canada, Germany, Korea, Republic of, Russian Federation, France, Israel, Hungary, Portugal, United Kingdom, Georgia, Ukraine
-
Bristol-Myers SquibbCompletedLocally Advanced (Unresectable) or Metastatic Adenocarcinoma of the Gastric and Gastro-esophageal JunctionFrance, Poland, Russian Federation, Taiwan, United States, Hong Kong, Spain, Germany, Italy, Japan, Korea, Republic of, Singapore
-
PfizerRecruitingLocally Advanced or Metastatic ER+ HER2- Breast Cancer | Locally Advanced or Metastatic Castration-resistant Prostate Cancer | Locally Advanced or Metastatic Non-small Cell Lung CancerUnited States, China, Australia, Korea, Republic of, Japan
-
AmgenTerminatedAdenocarcinoma of the Pancreas | Locally Advanced | UnresectableSpain, Belgium, Denmark, Poland, United States, Korea, Republic of, Russian Federation, Austria, Portugal, United Kingdom, Germany, Hungary, Czech Republic
-
National Cancer Institute (NCI)NRG OncologyActive, not recruitingUnresectable Breast Carcinoma | Stage IV Breast Cancer AJCC v6 and v7 | Stage III Breast Cancer AJCC v7 | Metastatic Breast Adenocarcinoma | Metastatic HER2-Positive Breast Carcinoma | Recurrent Breast Adenocarcinoma | Recurrent HER2-Positive Breast Carcinoma | Unresectable HER2-Positive Breast CarcinomaUnited States, Canada
-
Astellas Pharma Global Development, Inc.Active, not recruitingLocally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer | Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer | Metastatic Gastric Adenocarcinoma or Cancer | Metastatic Gastroesophageal Junction (GEJ) AdenocarcinomaUnited States, Korea, Republic of, China, Spain, Taiwan, Japan, Argentina, Canada, Croatia, Greece, Ireland, Malaysia, Netherlands, Portugal, Romania, Thailand, Turkey, United Kingdom
-
Astellas Pharma Global Development, Inc.Active, not recruitingLocally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer | Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer | Metastatic Gastric Adenocarcinoma or Cancer | Metastatic Gastroesophageal Junction (GEJ) AdenocarcinomaUnited States, Australia, Belgium, Brazil, Canada, Chile, China, Colombia, France, Germany, Israel, Italy, Japan, Korea, Republic of, Mexico, Peru, Poland, Spain, Taiwan, United Kingdom
-
Novartis PharmaceuticalsCompletedAdvanced Triple Negative Breast Cancer (TNBC) With High TAMsFrance, Italy, Austria, Taiwan, United States, Spain, Australia, Korea, Republic of, Belgium, Germany, Hong Kong, Turkey
-
Hoffmann-La RocheRecruitingEstrogen Receptor-Positive, HER2-Negative Advanced Breast CancerBelgium, Korea, Republic of, United States, Canada, China, Italy, France, Brazil, Australia, Argentina, Hong Kong, Portugal, Spain, Taiwan, India, Costa Rica, Israel, Thailand, Germany, New Zealand, Poland, Chile, Colombia, Guatemala, H...
-
Gilead SciencesRecruitingStage IV Breast Cancer | Locally Advanced or Unresectable Metastatic Breast CancerTaiwan, Korea, Republic of, Australia, Greece, Spain, United States, United Kingdom, France, Israel, Malaysia, Japan, Belgium, Poland, China, Germany, Czechia, Singapore, Hungary, Brazil, Italy, South Africa, Portugal, Argentina, Hong... and more
-
Jiangsu HengRui Medicine Co., Ltd.CompletedLocally Advanced or Metastatic and Unresectable HCCUnited States, Spain, China, Taiwan, Belgium, Korea, Republic of, Italy, Hong Kong, Russian Federation, Ukraine, Turkey, Poland, Germany
-
Novartis PharmaceuticalsCompletedMetastatic Breast Cancer | HER2/Neu Over-expressing Locally Advanced Breast CancerChina, United States, France, Hungary, Turkey, Japan, Germany, Singapore, Italy, Poland, Spain, United Kingdom, Thailand, Israel, Australia, Belgium, Greece, Argentina, Czech Republic, Mexico, Slovakia
-
CytomX TherapeuticsCompletedNeoplasms | Breast Cancer | Breast Neoplasms | Breast Neoplasms, Triple-Negative | Breast Neoplasms, Hormone Receptor Positive/HER2 NegativeUnited States, Spain, Korea, Republic of
-
Vanderbilt-Ingram Cancer CenterNational Cancer Institute (NCI); Genentech, Inc.; Translational Breast Cancer... and other collaboratorsTerminatedStage IV Breast Cancer | Estrogen Receptor Negative | Estrogen Receptor Positive | HER2/Neu Negative | Progesterone Receptor Negative | Progesterone Receptor Positive | Triple-Negative Breast CarcinomaUnited States
-
Hope Rugo, MDJohns Hopkins University; Pfizer; Gilead Sciences; Hoosier Cancer Research Network and other collaboratorsRecruitingStage IV Breast Cancer | Recurrent Breast Carcinoma | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Invasive Breast Carcinoma | Unresectable Breast Carcinoma | Stage IIIC Breast Cancer | Triple-Negative Breast Carcinoma | Stage III Breast CancerUnited States
-
Jules Bordet InstituteHoffmann-La Roche; Breast International Group; Institut Curie; International Drug...SuspendedHER2-positive Breast Cancer | ER-Negative Breast Cancer | PR-Negative Breast Cancer | Node-negative Breast CancerKorea, Republic of, France, Israel, Belgium, Switzerland, Australia
-
Vanderbilt-Ingram Cancer CenterNational Cancer Institute (NCI); Genentech, Inc.Active, not recruitingTriple Negative Breast Cancer | Invasive Breast Cancer | Stage IV Breast Cancer | HER2 NegativeUnited States
-
Mayo ClinicNational Cancer Institute (NCI)Enrolling by invitationAnatomic Stage III Breast Cancer AJCC v8 | Anatomic Stage IV Breast Cancer AJCC v8 | Recurrent Breast Carcinoma | Metastatic Triple-Negative Breast Carcinoma | Advanced Triple-Negative Breast CarcinomaUnited States
-
National Cancer Institute (NCI)CompletedRecurrent Breast Carcinoma | Estrogen Receptor Negative | Estrogen Receptor Positive | HER2/Neu Negative | HER2/Neu Positive | Progesterone Receptor Negative | Progesterone Receptor Positive | Stage IIIC Breast Cancer AJCC v6 | Stage IV Breast Cancer AJCC v6 and v7United States, Puerto Rico